Is DOCS a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Clinical AI moving from demo to daily use, with revenue (ttm through june 2026) at ~$656M. The bear case rests on revenue is concentrated: 127 customers were ~83% of trailing revenue, and most are pharmaceutical manufacturers whose promotional budgets move with drug launches, patent expirations and pricing policy. Analysts covering it are spread from $18.00 to $47.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Revenue is concentrated: 127 customers were ~83% of trailing revenue, and most are pharmaceutical manufacturers whose promotional budgets move with drug launches, patent expirations and pricing policy. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $18.00, -34.3% from the $27.40 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Clinical AI moving from demo to daily use. Doximity reported more than 800,000 active prescribers on its workflow tools in the March 2026 quarter, and in the June 2026 quarter said workflow active prescribers grew more than 30% year over year while AI Search queries rose more than 25% quarter over quarter. The most optimistic analyst target on DOCS is $47.00, +71.5% from the $27.40 price. That figure is only reachable if this thesis works close to its best case.

Revenue is concentrated: 127 customers were ~83% of trailing revenue, and most are pharmaceutical manufacturers whose promotional budgets move with drug launches, patent expirations and pricing policy. Net revenue retention of 107%, down from 118%, shows existing customers expanding far more slowly than they were a year ago. AI is a cost line before it is a revenue line here, with gross margin, adjusted EBITDA margin and stock compensation all moving the wrong way in the June 2026 quarter, and OpenEvidence, a free ad-supported clinical AI reference used by many of the same physicians, competes directly and has sued Doximity in federal court alleging unauthorized access to its platform (Doximity has filed counterclaims including false advertising and defamation). The securities class action that followed the fiscal 2024 guidance reset was settled for $31 million funded by insurance carriers, with final court approval on June 11, 2026 and the case terminated on June 23, 2026, but related shareholder derivative suits in California and Delaware remain pending. The stock has also been unstable in a way that is easy to underestimate: a ~$17.15 to ~$76.51 range over the past year, and an August 7, 2026 session that opened near ~$39 and closed near ~$27.40 on roughly six times normal volume. The most pessimistic published target is $18.00, -34.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Verified professional network for US physicians, monetized through pharma marketing, hiring and clinical-workflow tools including its Ask and Scribe AI products.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Clinical AI moving from demo to daily use) stalling in the reported numbers rather than in the narrative, the risk above (revenue is concentrated: 127 customers were ~83% of trailing revenue, and most are pharmaceutical manufacturers whose promotional budgets move with drug launches, patent expirations and pricing policy) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

The network is free for doctors. Doximity sells to the other side: pharmaceutical manufacturers buying Marketing Solutions to reach prescribers, health systems buying Hiring Solutions to recruit clinicians, and both buying Workflow Solutions such as the Dialer, digital fax, Amion scheduling and the Clinical AI Suite. Roughly 83% of trailing revenue came from 127 customers spending at least $500,000 a year.

Yes, on both GAAP and cash measures. Fiscal 2026 (ended March 31, 2026) net income was ~$196M on ~$645M of revenue, with ~$317M of free cash flow. Profit fell in the June 2026 quarter to ~$24.3M from ~$53.3M a year earlier, mainly on a step-up in stock-based compensation to ~$36.8M and a higher tax provision, not on any revenue shortfall.

Expectations were low after a weak March quarter and a soft initial fiscal 2027 guide had pushed the stock to a ~$17.15 low in May 2026. The June quarter then beat its own revenue guide by roughly $5M, adjusted EBITDA cleared the top of guidance, and management raised the full-year revenue range while highlighting AI adoption metrics. Shares gapped up toward ~$39 on August 7, faded through the day and closed near ~$27.40, up ~32%.